IPP Bureau
Philogen updates on Fibromun clinical study developments
By IPP Bureau - November 13, 2025
FIBROSARC did not meet its primary PFS endpoint in the final analysi
Biotronik selects Syensqo’s Eviva Polysulfone for pacemaker header components
By IPP Bureau - November 13, 2025
The high-performance polymer’s transparency and biocompatibility support precise implantation and long-term reliability
BASF and Beyond Suncare welcome WHO decision to list broad-spectrum sunscreen as “Essential Medicine”
By IPP Bureau - November 12, 2025
The inclusion of broad-spectrum sunscreen in the WHO EML and EMLc follows an application submitted in November 2024 by the Global Albinism Alliance
Novartis opens radioligand therapy manufacturing facility in California
By IPP Bureau - November 12, 2025
New site expands manufacturing footprint to meet future demand; ensures continued on-time delivery rate of >99.9% to patients across western US, Alaska and Hawaii
Tata 1mg boosts delivery speed with AI-driven logistics
By IPP Bureau - November 12, 2025
This partnership has led to a 10% boost in delivery speed
JB Pharma Q2 PAT up 19 % at Rs. 208 Cr
By IPP Bureau - November 12, 2025
Net profit for the half-year rose to Rs. 410 crore from Rs. 351 crore
Moraine appointed as distributor for OTSAW’s Hospital robots in Japan
By IPP Bureau - November 12, 2025
Moraine will serve as OTSAW’s exclusive distributor in Japan, deploying the Camello+ autonomous mobile robot and TransCar autonomous guided vehicle to support hospital logistics
AstraZeneca's Baxdrostat achieves breakthrough blood pressure reductions in Phase III Bax24 trial
By IPP Bureau - November 12, 2025
Patients on baxdrostat showed a significant reduction in systolic blood pressure (SBP) compared to placebo
Revvity launch new somatic cancer reference standards to to boost precision in oncology diagnostics
By IPP Bureau - November 12, 2025
The new MimixTM GeniTM reference standards were developed from the extensively tested Genome-in-a-Bottle Consortium (GIAB) cell line
Shilpa Medicare announces positive Phase 3 results for Oeris
By IPP Bureau - November 12, 2025
OERIS offers extended antiemetic coverage through a single injection that effectively prevents both acute and delayed CINV for up to five days
Samsung Epis launches new biotech subsidiary Epis NexLab
By IPP Bureau - November 12, 2025
The new company aims to transform cutting-edge, highly scalable technologies into innovative drug discovery platforms
FDA grants Orphan Drug Designation for Tinostamustine in malignant glioma
By IPP Bureau - November 12, 2025
Tinostamustine is an investigational drug with a potential first-in-class mechanism combining bifunctional alkylating activity and pan histone deacetylase (HDAC) inhibition
Synchron raises $200 million to power non-surgical brain interface commercialization
By IPP Bureau - November 11, 2025
New funding to advance non-surgical brain interface technology and expand clinical and engineering capabilities globally
Mount Sinai to implement Microsoft Dragon Copilot for clinical documentation
By IPP Bureau - November 11, 2025
Dragon Copilot integrates generative AI, ambient listening, and natural language processing (NLP) to capture and document care directly
Trump clinches historic deal as Lilly, Novo slash U.S. weight-loss drug prices
By IPP Bureau - November 11, 2025
Agreements mark a major victory in the President’s long-term pledge to lower prescription drug costs for Americans
